Regenxbio Inc (RGNX) Unusual Options Activity Today

Checking RGNX unusual options activity helps you spot when traders are making outsized bets on Regenxbio Inc before the broader market catches on. Regenxbio Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor RGNX unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching RGNX unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking RGNX unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and RGNX unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage.

REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Catalysts rarely arrive without a footprint, and RGNX unusual options activity is often where that footprint shows up first. Our scanner tracks Regenxbio Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at RGNX unusual options volume on the call side or chasing put sweeps, Regenxbio Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.